tirzepatide uti FDA Says Compounded Must Exit the Market Switch to Tirzepatide in T2D

It is a 47-residue synthetic peptide constructed as a D-retro-inverso (DRI) analog: the primary sequence is reversed and each amino acid is substituted with its D-enantiomer, an arrangement that approximates the topological side-chain presentation of the parent L-peptide while conferring markedly greater resistance to proteolytic degradation in typical aqueous and biological buffer systems used at the bench

They also have subscription benefits like auto-refills with discounts, so you never miss a dose

The drug is currently under regulatory review in the U.S., with a decision expected by April 10, 2026

The study's researchers hypothesized that the ratio of Bcl-2/Bax, proteins that appear to regulate cell death, were elevated, hinting at a possible protective role of AHK-Cu